Malignant Melanoma Archive - Seite 4 von 19 - IOZK

The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers

2018-09-26/in Breast Cancer, Glioblastoma, International Publications, Malignant Melanoma, Newcastle Disease Virus, Pancreatic Cancer

The Role of Oncolytic Viruses in the Treatment of Melanoma

2018-08-25/in International Publications, Malignant Melanoma, Newcastle Disease Virus

Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial)

2018-08-05/in Dendritic Cells, International Publications, Malignant Melanoma

Interim analysis of a prospective, randomized, double blind, placebo controlled, phase IIb trial of the TLPLDC vaccine to prevent recurrence in resected stage III or IV melanoma patients.

2018-06-04/in Dendritic Cells, International Publications, Malignant Melanoma

Molecular signatures associated with tumor-specific immune response in melanoma patients treated with dendritic cell-based immunotherapy

2018-03-30/in Dendritic Cells, International Publications, Malignant Melanoma

Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models

2018-03-26/in Dendritic Cells, International Publications, Malignant Melanoma

Proteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy

2018-03-18/in Dendritic Cells, International Publications, Malignant Melanoma

Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses

2018-03-06/in Dendritic Cells, International Publications, Malignant Melanoma

A prospective, randomized, blinded, placebo-controlled, phase IIb trial of an autologous tumor lysate + yeast cell wall particles (YCWP) + dendritic cells (DC) vaccine vs unloaded YCWP + DC and embedded phase I/IIa trial with tumor lysate particle only (TLPO) vaccine in stage III and stage IV (resected) melanoma to prevent recurrence.

2018-01-25/in Dendritic Cells, International Publications, Malignant Melanoma

An update on the relevance of vaccine research for the treatment of metastatic melanoma

2017-11-23/in Dendritic Cells, International Publications, Malignant Melanoma